Investment fuels AI-driven development of breakthrough genomic medicines
pharmaphorum
OCTOBER 12, 2022
He is mainly interested in the electronics and telecommunications sectors. For more information, please visit www.debiopharm.com/digital-health/ or follow @DebiopharmFund on Twitter. After an MBA at INSEAD in 2000, he joined the world of venture capital in the Seventures fund as a partner, then Omnes Capital in 2005.
Let's personalize your content